Companies › Teligene US
2 active drug programs in 3 registered trials: 3 Phase 2; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sutetinib Maleate Capsule EGFR tyrosine kinase inhibitor targeting uncommon mutations (L861Q, G719X, S768I) | EGFR | Phase 2 | Non-small Cell Lung Cancer | Dec 2027 |
| TL118 NTRK fusion inhibitor | NTRK1, NTRK2, NTRK3 | Phase 2 | Solid Tumor | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05168566 | Sutetinib Maleate Capsule | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT06010329 | Sutetinib Maleate Capsule | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT06010342 | TL118 | Phase 2 | Solid Tumor | Oncology | Dec 2027 |
Wayshine Biopharm Black Diamond Therapeutics Avistone Biotechnology NanoEcho Syncromune
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.